Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6729437 | 0.82 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL7047115 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL6726438 | 0.81 | PTGS2 (0.46) | PTGS2PTGS1 | |
| SCHEMBL6722877 | 0.80 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL6722092 | 0.80 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL6721832 | 0.79 | PTGS2 (0.41) | PTGS2PTGS1TGFBR1 | |
| SCHEMBL6718366 | 0.78 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL6718983 | 0.78 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL6721801 | 0.78 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL6718738 | 0.78 | PTGS2 (0.58) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885TGFBR1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.